Agentix Corp. is a clinical-stage biotechnology company developing peripherally-restricted therapeutics for metabolic diseases such as obesity and Type 2 diabetes, with no current revenue and operations focused on research, licensing, and trial preparation.

# Company Summary: Agentix Corp.

## Business Focus
- **Industry:** Biotechnology and pharmaceutical development  
- **Specialization:** Development of therapeutics targeting metabolic diseases, specifically focusing on "peripherally-restricted" drugs that do not cross the blood-brain barrier (BBB).

## Core Assets & Pipeline
- **Main Product Candidate:** AGTX-2004 (DBPR211)  
  - A peripherally-acting CB1 receptor antagonist designed to treat obesity and Type 2 diabetes mellitus (T2DM).  
  - Demonstrated efficacy in animal models; does not cross the BBB.  
  - Has received FDA clearance for an IND application, with plans to initiate Phase 1 safety and tolerability trials in Australia.

- **Additional Asset:** AGTX-2003 (RTI-1092769)  
  - Also a peripherally-acting CB1 receptor inverse agonist.  
  - Shows efficacy in animal models for obesity and non-alcoholic fatty liver disease (NAFLD).  
  - Currently being prepared for IND filing with the FDA.

- **License Agreements:**  
  - Exclusive worldwide rights to AGTX-2004 licensed from Taiwan’s National Health Research Institute (NHRI).  
  - License for technology related to pyrazole compounds for T2D, obesity, and fatty liver disease from Taiwan’s NHRI.

## Market & Industry Context
- **Market Drivers:**  
  - Increasing prevalence of metabolic syndrome, obesity, and Type 2 diabetes globally.  
  - Rising adoption of biopharmaceuticals and strategic industry partnerships.  
  - The market includes monoclonal antibodies, recombinant proteins, vaccines, and hormones.  
  - North America is a major market, with high growth projected in Asia Pacific.

- **Competitors:**  
  - Major biopharma companies like Novo Nordisk, Johnson & Johnson, Pfizer, Roche, Eli Lilly, Biogen, Merck, Sanofi, Bristol-Myers Squibb, Bayer.

## Business Stage & Operations
- **Stage:** Clinical development stage; no revenue has been generated yet.  
- **Employees:** None as of March 31, 2025.  
- **Operational Focus:**  
  - Research and development of drug candidates.  
  - Initiating and preparing for Phase 1 clinical trials.  
  - Developing intellectual property and licensing agreements.  

## Financial & Commercial Status
- **Revenue:** None reported for fiscal years ending March 31, 2024 and 2025.  
- **Net Loss:**  
  - Approximately **$567,048** in the year ending March 31, 2025  
  - Approximately **$585,154** in the year ending March 31, 2024  
- **Assets:**  
  - Total current assets of about **$100,274** as of March 31, 2025.  
  - No long-term assets reported.  
- **Liabilities:**  
  - Total liabilities of approximately **$3,204,523** as of March 31, 2025, mainly owed to related parties and vendors.  
- **Cash Position:**  
  - Approximately **$4,477** as of March 31, 2025.  
  - Significant doubt about the company's ability to continue as a going concern due to net losses and high liabilities.

## Key Highlights
- No full-time or part-time employees; operations managed by Rehan Huda, CEO and Director.  
- Focused on drug development, partnerships, licensing, and clinical trials rather than sales or commercial production at this stage.  
- The company is operating at a significant net loss, with no current revenue, and heavily reliant on external funding and licensing milestones to progress.

Agentix Corp. focuses on developing innovative pharmaceutical treatments for metabolic diseases, particularly obesity and type 2 diabetes mellitus.

# Company Summary: Agentix Corp.

## Overview
Agentix Corp., founded on April 18, 2013, in Nevada, is a clinical development stage corporation specializing in pharmaceutical treatments for metabolic diseases. The company shifted its focus from manufacturing composite products for the oil and gas industry to the development and commercialization of novel therapeutics targeting metabolic syndrome.

## Objectives
The primary business objective of Agentix is to develop two key pharmaceutical assets designed to be "peripherally-restricted," meaning they do not cross the blood-brain barrier (BBB). These assets aim to address metabolic disorders, including obesity, insulin resistance, and type 2 diabetes mellitus (T2DM).

## Key Products in Development
### 1. **AGTX-2004 (DBPR211)**
   - **Type:** Peripherally-acting CB1 receptor antagonist.
   - **Efficacy:** Demonstrated effectiveness in animal models for obesity and T2DM.
   - **Approval Status:** Investigational New Drug (IND) application cleared by the FDA; Phase 1 safety study preparation is underway.
   - **License Agreement:** Worldwide exclusive rights obtained from Taiwan’s National Health Research Institute (NHRI) with milestone payments and royalties.

### 2. **AGTX-2003 (RTI-1092769)**
   - **Type:** Peripherally-acting CB1 receptor inverse agonist.
   - **Efficacy:** Effective in animal models for obesity and non-alcoholic fatty liver disease (NAFLD).
   - **Current Status:** Additional enabling animal studies are ongoing for future IND application filing.
   - **License Agreement:** Exclusive worldwide rights acquired from Research Triangle Institute (RTI).

## Business Structure
- **Subsidiaries:** 
  - **Agentix Australia Pty Ltd:** Established in September 2022 for development activities and benefiting from tax rebates on biotechnology activities in Australia.

## Financial Overview
- **Revenue:** The company has not generated meaningful revenues as it is still in the clinical development stage.
- **Research and Development (R&D) Costs:** 
  - FY 2024: $175,268 
  - FY 2023: $711,506

## Employment
- The company currently has **no full-time or part-time employees**, operating primarily through its director, Rehan Huda.

## Customer Base
- Agentix does not have a defined customer base since it is in the clinical stage and has not yet commercialized its products.

## Company Address
- **Location:** 32932 Pacific Coast Highway, #14-254, Dana Point, California 92629.

## Summary
Agentix Corp. is focused on addressing significant health challenges associated with metabolic syndromes through the development of innovative peripherally-restricted therapeutics. While it has made strides in obtaining licensing agreements and initiating clinical study preparations, it remains in the early stages of product development with no reported revenues or customers to date.

Agentix Corp.

10-K / July 16, 2025

10-K / August 30, 2024

10-K / July 16, 2025

Company Summary: Agentix Corp.

Business Focus

Core Assets & Pipeline

Market & Industry Context

Business Stage & Operations

Financial & Commercial Status

Key Highlights